Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.
|Original language||English (US)|
|Journal||Canadian Journal of Neurological Sciences|
|Issue number||6 SUPPL.6|
|State||Published - Nov 1 2012|
ASJC Scopus subject areas
- Clinical Neurology